Our top pick for
Galapagos NV is a biotechnology business based in the US. Galapagos shares (GLPG) are listed on the NASDAQ and all prices are listed in US Dollars. Galapagos employs 1,397 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$50.93|
|52-week range||$48.66 - $130.26|
|50-day moving average||$53.95|
|200-day moving average||$65.74|
|Wall St. target price||$79.92|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.47|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||-1.39%|
|1 month (2021-09-24)||-4.71%|
|3 months (2021-07-23)||-14.99%|
|6 months (2021-04-23)||-37.48%|
|1 year (2020-10-23)||-60.10%|
|2 years (2019-10-25)||-69.41%|
|3 years (2018-10-25)||97.04|
|5 years (2016-10-25)||64.79|
|Revenue TTM||$590.3 million|
|Gross profit TTM||$6.6 million|
|Return on assets TTM||-1.57%|
|Return on equity TTM||-8.05%|
|Market capitalisation||$3.3 billion|
TTM: trailing 12 months
There are currently 433,037 Galapagos shares held short by investors – that's known as Galapagos's "short interest". This figure is 17.7% up from 367,785 last month.
There are a few different ways that this level of interest in shorting Galapagos shares can be evaluated.
Galapagos's "short interest ratio" (SIR) is the quantity of Galapagos shares currently shorted divided by the average quantity of Galapagos shares traded daily (recently around 254727.64705882). Galapagos's SIR currently stands at 1.7. In other words for every 100,000 Galapagos shares traded daily on the market, roughly 1700 shares are currently held short.
However Galapagos's short interest can also be evaluated against the total number of Galapagos shares, or, against the total number of tradable Galapagos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galapagos's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Galapagos shares in existence, roughly 10 shares are currently held short) or 0.01% of the tradable shares (for every 100,000 tradable Galapagos shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Galapagos.
Find out more about how you can short Galapagos stock.
We're not expecting Galapagos to pay a dividend over the next 12 months.
Over the last 12 months, Galapagos's shares have ranged in value from as little as $48.66 up to $130.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galapagos's is 0.3708. This would suggest that Galapagos's shares are less volatile than average (for this exchange).
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc. ; AbbVie S. à r.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.